ICU Sedation Protocol

Recent Updates

• Aligned with the 2025 PADIS focused update, which adds anxiety as a managed symptom and conditionally favors dexmedetomidine over propofol when light sedation or delirium reduction is the priority.
• The 2025 A2B trial found no extubation benefit for dexmedetomidine over propofol and more severe bradycardia, so agent choice is framed as individualized.
• Antipsychotics are no longer recommended to treat delirium itself per the 2025 update, and melatonin is now suggested to support sleep.

Source: Lewis K, Balas MC, Stollings JL, et al. A Focused Update to the PADIS Clinical Practice Guidelines (2025). Crit Care Med 2025;53(3):e711–e727. doi:10.1097/CCM.0000000000006574. Walsh TS, et al. A2B trial. JAMA 2025;334(1):32–45.

About This ICU Sedation Protocol Tool

This interactive clinical tool translates the latest evidence from the PADIS (Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption) guidelines into a practical, point-of-care decision support algorithm. Proper management of these symptoms is a cornerstone of modern critical care, directly impacting patient outcomes. This ICU sedation protocol is designed to promote a calm, comfortable state while minimizing deep sedation and prioritizing patient-centered care.

By systematically evaluating the patient’s phenotype—whether their distress is driven by pain, anxiety, or delirium—clinicians can select more targeted therapies. This approach is an integral part of the ICU Liberation (ABCDEF) Bundle, specifically addressing components C (Choice of Analgesia and Sedation) and D (Delirium: Assess, Prevent, and Manage).

Algorithm Principles Explained

The “Analgesia-First” Cornerstone

The principle of “analgesia-first” or “analgosedation” is the foundation of this ICU sedation protocol. It recognizes that unresolved pain is a major physiological stressor and a primary driver of agitation. Before escalating sedation, it is imperative to assess and treat pain adequately. In many cases, effective pain control eliminates the need for dedicated sedative agents.

Phenotype-Specific Management

Modern guidelines emphasize a nuanced approach based on the patient’s specific presentation. This tool helps differentiate between phenotypes to guide more precise therapy:

• Anxiety-Dominant: This state is distinct from agitation. Management should focus on anxiolysis. Dexmedetomidine is often preferred due to its ability to relieve anxiety and promote a cooperative state without causing significant respiratory depression. Both dexmedetomidine and propofol are reasonable; dexmedetomidine is favored when avoiding respiratory depression and preserving a cooperative state are priorities, weighed against its risk of bradycardia (2025 A2B trial).
• Hyperactive Delirium: Characterized by agitation and restlessness in a delirious patient. The goal is to provide safe sedation while avoiding agents that could worsen delirium, such as benzodiazepines. Antipsychotics such as quetiapine are not recommended to treat delirium itself (2025 PADIS) and should be reserved for short-term control of severe distressing agitation only.
• Hypoactive Delirium: This common but often-missed state requires a focus on non-pharmacologic interventions, lightening sedation, and promoting mobility. Over-sedation is a key risk factor that must be avoided.

Multimodal, Opioid-Sparing Strategies

To mitigate the significant side effects of high-dose opioids, a multimodal strategy is now the standard of care. This involves combining different classes of analgesics. This tool recommends considering agents like low-dose Ketamine infusions, which provide excellent analgesia via NMDA receptor antagonism, or Remifentanil infusions in patients with severe organ dysfunction. These strategies reduce total opioid exposure.

Proactive Sleep Management

Sleep disruption is a critical, modifiable risk factor for delirium. This protocol emphasizes protecting the natural sleep-wake cycle. Pharmacologically, sedative choice matters. Agents like Dexmedetomidine are often preferred for nighttime sedation as they are less disruptive to natural sleep architecture compared to Propofol and benzodiazepines. The 2025 PADIS focused update also suggests melatonin to support the sleep-wake cycle in adult ICU patients.

Frequently Asked Questions (FAQ)

1. What is the goal of a modern ICU sedation protocol?

The primary goal is to maintain a light level of sedation whenever possible. This involves using the lowest effective dose of medication to ensure the patient is comfortable and safe, but easily arousable. This approach, part of the ICU Liberation Bundle, is associated with better outcomes, including shorter ventilation times and reduced delirium.

2. Why are benzodiazepines (e.g., Midazolam) generally avoided?

Extensive research has linked the routine use of benzodiazepines for ICU sedation to a higher incidence and longer duration of delirium, prolonged mechanical ventilation, and increased ICU length of stay compared to non-benzodiazepine sedatives like Propofol or Dexmedetomidine.

3. When should antipsychotics like Quetiapine or Haloperidol be used for delirium?

The 2025 PADIS focused update makes no recommendation for or against antipsychotics (haloperidol or atypical agents such as Quetiapine) to treat delirium, because current evidence shows little or no effect on patient-important outcomes. Antipsychotics are not recommended for routine delirium treatment; if used, reserve them for short-term control of severe distress or agitation that threatens safety, alongside treating the underlying causes and prioritizing non-pharmacologic interventions first.

4. Can this tool be used for non-intubated patients?

Yes. The principles of pain and delirium management are the same. For sedation, the choice of agent is even more critical. Dexmedetomidine is an ideal choice for non-intubated patients as it provides cooperative sedation without causing significant respiratory depression.

5. What is the ICU Liberation (ABCDEF) Bundle?

It is a set of evidence-based practices aimed at improving ICU patient outcomes. The components are: Assess, Prevent, and Manage Pain; Both Spontaneous Awakening and Breathing Trials; Choice of Analgesia and Sedation; Delirium: Assess, Prevent, and Manage; Early Mobility and Exercise; and Family Engagement and Empowerment.